LTGO

Latigo Biotherapeutics, Inc. Common Stock

Price Chart

Latest Quote

$18.25

+0.25 (+1.39%)

Current Price

Previous Close	$18.00
Open	$21.00
Day High	$22.47
Day Low	$18.19
Volume	3,286,704

Fetched: 2026-08-08T03:27:04

Stock Information

Shares Outstanding	60.15M
Total Debt	$554K
Cash Equivalents	$42.18M
Net Income	$-111.18M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.10B
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$355.43M
Income	$-111.18M
Book/sh	$-42.49
Cash/sh	$0.70
Employees	59

Financial Ratios

Quick Ratio	2.91
Current Ratio	3.23
Debt/Eq	1.54

Returns & Margins

Ownership

Insider & Institutional transactions data not available

Valuation Ratios

P/B

-0.43

Analyst Data

Recommendation

none

Technical Indicators

Performance History

YTD

+0.00%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-08-07	$18.25	3,301,700

About Latigo Biotherapeutics, Inc. Common Stock

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.

📰 Latest News

No news articles available at the moment. Check back later for updates on LTGO.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31
Revenue
Total Revenue	$0	$0
Operating Revenue	$0	$0
Expenses
Total Expenses	$110,392,000	$63,451,000
Other Income Expense	$-1,718,000	$4,000
Other Non Operating Income Expenses	$-1,718,000	$4,000
Net Non Operating Interest Income Expense	$2,943,000	$2,264,000
Operating Expense	$110,392,000	$63,451,000
General And Administrative Expense	$10,862,000	$6,667,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-109,167,000	$-61,183,000
Net Interest Income	$2,943,000	$2,264,000
Interest Income	$2,943,000	$2,264,000
Normalized Income	$-109,167,000	$-61,183,000
Net Income From Continuing And Discontinued Operation	$-109,167,000	$-61,183,000
Total Operating Income As Reported	$-110,392,000	$-63,451,000
Net Income Common Stockholders	$-109,167,000	$-61,183,000
Net Income	$-109,167,000	$-61,183,000
Net Income Including Noncontrolling Interests	$-109,167,000	$-61,183,000
Net Income Continuous Operations	$-109,167,000	$-61,183,000
Pretax Income	$-109,167,000	$-61,183,000
Interest Income Non Operating	$2,943,000	$2,264,000
Operating Income	$-110,392,000	$-63,451,000
Other
Tax Effect Of Unusual Items	$0	$0
Tax Rate For Calcs	$0	$0
Normalized EBITDA (Bullshit earnings)	$-110,143,000	$-63,207,000
Reconciled Depreciation	$249,000	$244,000
EBITDA (Bullshit earnings)	$-110,143,000	$-63,207,000
EBIT	$-110,392,000	$-63,451,000
Diluted NI Availto Com Stockholders	$-109,167,000	$-61,183,000
Research And Development	$99,530,000	$56,784,000
Selling General And Administration	$10,862,000	$6,667,000
Other Gand A	$3,691,000	$2,476,000
Salaries And Wages	$7,171,000	$4,191,000

Fetched: 2026-08-08

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31
Assets
Net Tangible Assets	$-231,674,000	$-129,599,000
Total Assets	$75,516,000	$22,864,000
Total Non Current Assets	$1,687,000	$1,700,000
Other Non Current Assets	$616,000	$290,000
Current Assets	$73,829,000	$21,164,000
Restricted Cash	$192,000	$0
Prepaid Assets	$4,200,000	$3,246,000
Cash Cash Equivalents And Short Term Investments	$69,437,000	$17,918,000
Cash And Cash Equivalents	$69,437,000	$17,918,000
Debt
Total Debt	$690,000	$851,000
Long Term Debt And Capital Lease Obligation	$127,000	$464,000
Current Debt And Capital Lease Obligation	$563,000	$387,000
Liabilities
Total Liabilities Net Minority Interest	$307,190,000	$152,463,000
Total Non Current Liabilities Net Minority Interest	$288,744,000	$138,028,000
Other Non Current Liabilities	$35,000	$35,000
Current Liabilities	$18,446,000	$14,435,000
Payables And Accrued Expenses	$13,680,000	$11,774,000
Payables	$5,015,000	$7,068,000
Accounts Payable	$5,015,000	$7,068,000
Other Current Liabilities	-	$250,000
Equity
Common Stock Equity	$-231,674,000	$-129,599,000
Total Equity Gross Minority Interest	$-231,674,000	$-129,599,000
Stockholders Equity	$-231,674,000	$-129,599,000
Retained Earnings	$-243,131,000	$-133,964,000
Preferred Securities Outside Stock Equity	$288,582,000	$137,529,000
Other
Tangible Book Value	$-231,674,000	$-129,599,000
Invested Capital	$-231,674,000	$-129,599,000
Working Capital	$55,383,000	$6,729,000
Capital Lease Obligations	$690,000	$851,000
Total Capitalization	$-231,674,000	$-129,599,000
Additional Paid In Capital	$11,457,000	$4,365,000
Capital Stock	$0	$0
Common Stock	$0	$0
Long Term Capital Lease Obligation	$127,000	$464,000
Current Capital Lease Obligation	$563,000	$387,000
Pensionand Other Post Retirement Benefit Plans Current	$4,203,000	$2,024,000
Current Accrued Expenses	$8,665,000	$4,706,000
Net PPE	$1,071,000	$1,410,000
Accumulated Depreciation	$-854,000	$-605,000
Gross PPE	$1,925,000	$2,015,000
Other Properties	$1,825,000	$1,949,000
Machinery Furniture Equipment	$100,000	$66,000

Fetched: 2026-08-08

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31
Free Cash Flow
Free Cash Flow	$-97,693,000	$-51,027,000
Operating Activities
Operating Cash Flow	$-97,557,000	$-50,955,000
Cash Flow From Continuing Operating Activities	$-97,557,000	$-50,955,000
Investing Activities
Capital Expenditure	$-136,000	$-72,000
Investing Cash Flow	$-136,000	$-72,000
Cash Flow From Continuing Investing Activities	$-136,000	$-72,000
Financing Activities
Issuance Of Capital Stock	$149,379,000	$337,000
Financing Cash Flow	$149,496,000	$607,000
Cash Flow From Continuing Financing Activities	$149,496,000	$607,000
Net Preferred Stock Issuance	$149,379,000	$0
Preferred Stock Issuance	$149,379,000	$0
Net Common Stock Issuance	$0	$337,000
Common Stock Issuance	$0	$337,000
Other
End Cash Position	$69,721,000	$17,918,000
Beginning Cash Position	$17,918,000	$68,338,000
Changes In Cash	$51,803,000	$-50,420,000
Proceeds From Stock Option Exercised	$117,000	$270,000
Net PPE Purchase And Sale	$-136,000	$-72,000
Purchase Of PPE	$-136,000	$-72,000
Change In Working Capital	$2,518,000	$6,887,000
Change In Other Current Liabilities	$-446,000	$-352,000
Change In Other Current Assets	$-234,000	$98,000
Change In Payables And Accrued Expense	$4,177,000	$9,300,000
Change In Accrued Expense	$6,138,000	$3,548,000
Change In Payable	$-1,961,000	$5,752,000
Change In Account Payable	$-1,961,000	$5,752,000
Change In Prepaid Assets	$-979,000	$-2,159,000
Other Non Cash Items	$444,000	$327,000
Stock Based Compensation	$6,725,000	$2,770,000
Unrealized Gain Loss On Investment Securities	$1,674,000	$0
Depreciation Amortization Depletion	$249,000	$244,000
Depreciation And Amortization	$249,000	$244,000
Depreciation	$249,000	$244,000
Net Income From Continuing Operations	$-109,167,000	$-61,183,000

Fetched: 2026-08-08